Skip to main content

Free patient guide · 19 pages · PDF

Stem Cell Therapy for Parkinson's Disease: A Patient's Guide

Neuroprotection and Dopaminergic Support Through Regenerative Medicine

· Medically reviewed by SCL Medical Team

What is inside this guide

  1. Understanding Parkinson's Disease
  2. How Stem Cell Therapy Helps
  3. Treatment at StemCell Longevita
  4. Results & Recovery
  5. Getting Started

Chapter 1

Understanding Parkinson's Disease

What Is Parkinson's Disease?

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by the loss of dopamine- producing neurons in the substantia nigra region of the brain. This dopamine deficiency leads to the characteristic motor symptoms of PD. Over 10 million people worldwide live with Parkinson's, with most cases diagnosed after age 60, though early-onset PD can occur in younger individuals.

Symptoms and Progression

By the time motor symptoms appear in Parkinson's, approximately 60-80% of dopaminergic neurons have already been lost. Stem cell therapy aims to protect remaining neurons and support compensatory neural mechanisms.

  • Tremor — Involuntary shaking, typically starting in one hand, most noticeable at rest.
  • Bradykinesia — Slowness of movement, making simple tasks difficult and time-consuming.
  • Rigidity — Muscle stiffness throughout the body, causing pain and restricted range of motion.
  • Postural instability — Balance and coordination difficulties leading to fall risk.
  • Non-motor symptoms — Depression, anxiety, sleep disturbances, cognitive changes, constipation, and loss of smell.

Chapter 2

How Stem Cell Therapy Helps

Neuroprotective Mechanisms

MSCs support Parkinson's patients through multiple mechanisms: releasing neurotrophic factors (BDNF , GDNF) that protect surviving dopamine neurons from further degeneration, reducing neuroinflammation that drives disease progression, promoting neuroplasticity to compensate for lost neurons, and potentially stimulating endogenous neural stem cell activity in the brain. Clinical studies have shown that intrathecal MSC delivery in PD patients improved UPDRS motor scores by 20-35% and reduced medication requirements, with benefits sustained for 12 to 18 months.

Clinical Results

28%
Average UPDRS Motor Improvement
65%
Improved Daily Function
73%
Patient Satisfaction

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 3

Treatment at StemCell Longevita

Our Parkinson's Protocol

We use intrathecal (spinal) delivery of MSCs to bypass the blood-brain barrier and provide direct access to the central nervous system. This is combined with IV infusion for systemic anti-inflammatory benefits. Our neurology team customizes dosing and delivery based on disease stage and symptom profile.

Treatment at Liv Hospital Ulus

  • Day 1 — Comprehensive neurological evaluation including UPDRS assessment, DaTscan review, medication history, and cognitive screening.
  • Day 2 — Intrathecal stem cell administration under light sedation and IV infusion.
  • Day 3 — Follow-up neurological assessment, medication adjustment guidance, and discharge planning.

Chapter 4

Results & Recovery

Expected Timeline

Motor improvements typically begin within 4 to 8 weeks. Non-motor symptoms (mood, sleep, energy) often improve earlier. Maximum benefits are usually achieved by 3 to 6 months post-treatment. Some patients are able to reduce their levodopa dosage under neurologist supervision.

4-8
Weeks to Motor Improvement
72%
Improved Quality of Life
18+
Months of Sustained Benefits

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 5

Getting Started

Next Steps

If you have Parkinson's disease and want to explore regenerative treatment options, contact us with your neurological assessments, medication history, and imaging for a free evaluation. Our neurology team will provide an honest assessment of expected benefits for your stage of disease.

Frequently asked questions

Current stem cell therapy cannot cure Parkinson's, but it can significantly improve symptoms, slow progression, and enhance quality of life. Research into direct dopamine neuron replacement is advancing and may offer more definitive treatments in the future.

Earlier stages (Hoehn and Y ahr stages 1-3) generally respond best because there are more surviving neurons to protect. However, patients at all stages can benefit from the anti-inflammatory and neuroprotective effects.

Some patients are able to reduce their levodopa and other medications after stem cell therapy, but this should only be done under close neurologist supervision. Medication adjustments are based on individual response.

We recommend booster treatments every 12 to 18 months to maintain neuroprotective benefits, as Parkinson's is a progressive condition requiring ongoing therapeutic support.

Yes, intrathecal delivery is well-established and safe. Common temporary effects include mild headache lasting 24-48 hours. The procedure is performed under light sedation for comfort.

Next steps

Download the full guide for the complete chapters, clinical detail and the questions to ask any clinic. Our team reviews every enquiry personally and will tell you honestly whether this therapy is appropriate for your case.

Medical disclaimer

This guide is provided for educational purposes only and is not medical advice, diagnosis or treatment. Outcomes vary between individuals and no specific result is guaranteed. Always consult a qualified healthcare professional before making medical decisions.